{
    "clinical_study": {
        "@rank": "85769", 
        "arm_group": [
            {
                "arm_group_label": "Control Arm", 
                "arm_group_type": "Active Comparator", 
                "description": "Standard chemotherapy (Cisplatin or Carboplatin) and  IMRT (Intensity-Modulated Radiation Therapy)"
            }, 
            {
                "arm_group_label": "Boost Arm", 
                "arm_group_type": "Experimental", 
                "description": "Boost radiation to hypoperfused volumes in addition to standard chemotherapy (Cisplatin or Carboplatin) and  IMRT (Intensity-Modulated Radiation Therapy)"
            }
        ], 
        "brief_summary": {
            "textblock": "This study aims to improve locoregional control of poor prognosis Head and Neck Cancer (HNC)\n      patients by selectively escalating the radiotherapy dose to subvolumes of tumor likely to be\n      resistant to standard Radiation Therapy (RT) using DCE-MRI (Dynamic Contrast Enhanced\n      Magnetic Resonance Imaging).  Standard doses of radiotherapy to the rest of the tissues and\n      surrounding normal tissues will be maintained."
        }, 
        "brief_title": "Randomized Phase II Study of DCE-MRI-based Dose Escalation for Poor-prognosis and Neck Cancer", 
        "condition": "Squamous Cell Carcinoma of the Head and Neck", 
        "condition_browse": {
            "mesh_term": [
                "Carcinoma", 
                "Carcinoma, Squamous Cell", 
                "Head and Neck Neoplasms"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Patients must have pathologically\u2010confirmed, previously untreated, non\u2010metastatic\n             locally/regionally advanced squamous cell carcinoma of the head and neck, stage\n             III/IV, referred for definitive chemo\u2010RT, and meet one of the following six criteria:\n\n               1. Primary tumor and/or metastatic lymph nodes are: unresectable, resection is\n                  considered by the treating surgeon or patient to result in unacceptable\n                  functional or oncological results, patient refuses surgery, or surgery is not\n                  possible due to comorbidities.\n\n               2. HPV(\u2010) (Human Papillomavirus) locally/regionally advanced (T3\u20104 or N2\u20103)\n                  oropharyngeal cancer.\n\n               3. HPV(+) locally/regionally advanced (T4 or N3) oropharyngeal cancer.\n\n               4. Locally advanced, bulky (>6 cc*) T3 or T4 laryngeal or hypopharyngeal cancer in\n                  patients who decline surgery.\n\n               5. Stage III/IV oral cavity or paranasal sinus cancers in patients who refuse\n                  surgery or are unfit for surgery.\n\n               6. Locally/regionally advanced (stage T3\u20104 and/or N3) nasopharyngeal cancer which\n                  is EBV (\u2010) (Epstein\u2010Barr Virus).\n\n          -  KPS (Karnofsky Performance Status:  A measure of general well being and activities of\n             daily living; scores range from 0 to 100 where 100 represents perfect health) >70\n             (see Appendix A) within two weeks of enrollment.\n\n          -  Pre\u2010treatment laboratory criteria within four weeks of enrolment:\n\n          -  WBC (White Blood Cell) > 3500/ul, granulocyte > 1500/ul.\n\n          -  Platelet count > 100,000/ul.\n\n          -  Total Bilirubin < 1.5 X ULN.\n\n          -  AST (Aspartate Aminotransferase) and ALT (Alanine Aminotransferase) < 2.5 X ULN.\n\n          -  Estimated Creatinine clearance >30cc/min.\n\n          -  Patients are adults (Age >18).\n\n          -  All patients must be informed of the investigational nature of this study and given\n             written informed consent in accordance with institutional and federal guidelines.\n\n        Exclusion Criteria:\n\n          -  EBV (+) Nasopharyngeal Carcinoma.\n\n          -  Prior head and neck malignancy within the past 3 years. Patients with skin cancer or\n             early stage treated prostate cancer are eligible to participate.\n\n          -  Prior head and neck radiation or chemotherapy.\n\n          -  Documented evidence of distant metastases.\n\n          -  Patients with active infection.\n\n          -  Pregnant women.\n\n          -  Patients should have no contraindications to having a contrast enhanced MRI scan.\n             These contraindications will be assessed at the time of enrollment using the\n             guidelines set up and in clinical use by the Institutional Standard Practice."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "40", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "December 12, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02031250", 
            "org_study_id": "UMCC 2013.062", 
            "secondary_id": "HUM00074305"
        }, 
        "intervention": [
            {
                "arm_group_label": [
                    "Control Arm", 
                    "Boost Arm"
                ], 
                "description": "Cisplatin 40mg/m2 administered as an IV infusion prior to radiotherapy on day 1 of each week of chemo-irradiation", 
                "intervention_name": "Cisplatin", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": [
                    "Control Arm", 
                    "Boost Arm"
                ], 
                "description": "Patients considered medically unfit to receive Cisplatin as determined by the prescribing physician, will receive Carboplatin via IV infusion on day 1 of each week of chemo-irradiation", 
                "intervention_name": "Carboplatin", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": [
                    "Control Arm", 
                    "Boost Arm"
                ], 
                "intervention_name": "IMRT (Intensity-Modulated Radiation Therapy)", 
                "intervention_type": "Radiation"
            }, 
            {
                "arm_group_label": "Boost Arm", 
                "intervention_name": "Boost Radiation to Hypoperfused Volumes", 
                "intervention_type": "Radiation"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Cisplatin", 
                "Carboplatin"
            ]
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "lastchanged_date": "May 23, 2014", 
        "location": [
            {
                "contact": {
                    "last_name": "Avraham Eisbruch, M.D.", 
                    "phone": "734-936-4302"
                }, 
                "facility": {
                    "address": {
                        "city": "Ann Arbor", 
                        "country": "United States", 
                        "state": "Michigan", 
                        "zip": "48109"
                    }, 
                    "name": "University of Michigan Hospital"
                }, 
                "investigator": {
                    "last_name": "Avraham Eisbruch, M.D.", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Cora Edwards, C.C.R.P.", 
                    "phone": "734-222-8607"
                }, 
                "facility": {
                    "address": {
                        "city": "Ann Arbor", 
                        "country": "United States", 
                        "state": "Michigan", 
                        "zip": "48105"
                    }, 
                    "name": "Veterans Affairs (VA) Ann Arbor Healthcare System"
                }, 
                "status": "Not yet recruiting"
            }
        ], 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "2", 
        "official_title": "Randomized Phase II Study of DCE-MRI-based Dose Escalation for Poor-prognosis and Neck Cancer", 
        "overall_contact": {
            "email": "eisbruch@umich.edu", 
            "last_name": "Avraham Eisbruch, M.D.", 
            "phone": "734-936-4302"
        }, 
        "overall_official": {
            "affiliation": "University of Michigan Cancer Center", 
            "last_name": "Avraham Eisbruch, M.D.", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "December 2020", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Kaplan\u2010Meier curves with point\u2010wise 90% confidence intervals will be generated for each treatment arm, overall and by strata. Estimates with confidence intervals will be generated from these curves for the usual summary statistics, including median DFS times and DFS at 1, 2, and 3 years.", 
            "measure": "Disease Free Survival (DSF) time", 
            "safety_issue": "No", 
            "time_frame": "3 years post treatment"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02031250"
        }, 
        "responsible_party": {
            "investigator_affiliation": "University of Michigan Cancer Center", 
            "investigator_full_name": "Avraham Eisbruch", 
            "investigator_title": "Professor, Radiation Oncology", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": [
            {
                "description": "Compare local\u2010regional control rates between the two arms at 1, 2 and 3 years.  Local-regional control is defined as the absence of local\u2010regional progression.", 
                "measure": "Local-regional control rate", 
                "safety_issue": "No", 
                "time_frame": "3 years post-treatment"
            }, 
            {
                "measure": "Proportion of patients in which hypoperfused subvolumes overlap with recurrence volumes", 
                "safety_issue": "No", 
                "time_frame": "3 years post treatment"
            }, 
            {
                "description": "Acute and late toxicities will be summarized descriptively by grade and type for each treatment group. The proportion of patients experiencing certain toxicity types will be calculated with score based confidence intervals. Chi\u2010square tests will be used to test whether the proportion of patients with toxicity differs between treatment groups.", 
                "measure": "Number of patients with adverse events", 
                "safety_issue": "Yes", 
                "time_frame": "3 years post treatment"
            }, 
            {
                "description": "Pearson or Spearman rank based correlation between the continuous dose and perfusion summary measures", 
                "measure": "Correlation coefficient between continuous dose and perfusion summary measures", 
                "safety_issue": "No", 
                "time_frame": "2 weeks post Radiation Therapy (RT)"
            }
        ], 
        "source": "University of Michigan Cancer Center", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "University of Michigan Cancer Center", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "February 2014", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}